mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme

Ramaiah, M. Janaki; Kumar, K Rohil

doi:10.1007/s11033-021-06462-2

Cited by 20 publications

(7 citation statements)

References 206 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to chromatin remodeling, HDACs affect non-histone proteins at specific sites, including tumor suppressors [31][32][33] and oncoproteins [34,35] involved in tumor signaling pathways, ultimately affecting cell fate [36]. HDACs deacetylate many groups of non-histone proteins including: transcription factors [37][38][39], cell adhesion proteins [40,41], cellular proteins [42], DNA repair proteins [43], cell signaling proteins [44,45], and viral proteins [46] (Figure 1C). However, HDACs role in tumorigenesis is controversial: either promoting cancer cell survival or causing cell death among different types of cancers [47][48][49][50].…”

Section: Epigenetic Basis Of Cancermentioning

confidence: 99%

Vorinostat (SAHA) and Breast Cancer: An Overview

Wawruszak

Borkiewicz

Okon

et al. 2021

Cancers

View full text Add to dashboard Cite

Vorinostat (SAHA), an inhibitor of class I and II of histone deacetylases, is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006. HDIs are promising anticancer agents that inhibit the proliferation of many types of cancer cells including breast carcinoma (BC). BC is a heterogeneous disease with variable biological behavior, morphological features, and response to therapy. Although significant progress in the treatment of BC has been made, high toxicity to normal cells, serious side effects, and the occurrence of multi-drug resistance limit the effective therapy of BC patients. Therefore, new active agents which improve the effectiveness of currently used regimens are highly needed. This manuscript analyzes preclinical and clinical trials data of SAHA, applied individually or in combination with other anticancer agents, considering different histological subtypes of BC.

show abstract

Section: Epigenetic Basis Of Cancermentioning

confidence: 99%

Vorinostat (SAHA) and Breast Cancer: An Overview

Wawruszak

Borkiewicz

Okon

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Kumar et al . showed that the mTOR‑Rictor‑EGFR axis played a vital role in glioblastoma [ 40 ]. Cui et al .…”

Section: Discussionmentioning

confidence: 99%

Downregulation of NEDD4L by EGFR signaling promotes the development of lung adenocarcinoma

Song

et al. 2022

J Transl Med

View full text Add to dashboard Cite

Cumulative evidence indicates that the abnormal regulation of the NEDD4 family of E3-ubiquitin ligases participates in the tumorigenesis and development of cancer. However, their role in lung adenocarcinoma (LUAD) remains unclear. This study comprehensively analyzed the NEDD4 family in LUAD data sets from public databases and found only NEDD4L was associated with the overall survival of LUAD patients. Gene set enrichment analysis (GSEA) indicated that NEDD4L might be involved in the regulation of mTORC1 pathway. Both cytological and clinical assays showed that NEDD4L inhibited the activity of the mTOR signaling pathway. In vivo and in vitro experiments showed that NEDD4L could significantly inhibit the proliferation of LUAD cells. In addition, this study also found that the expression of NEDD4L was regulated by EGFR signaling. These findings firstly revealed that NEDD4L mediates an interplay between EGFR and mTOR pathways in LUAD, and suggest that NEDD4L held great potential as a novel biomarker and therapeutic target for LUAD.

show abstract

“…Of note, a number of cancers have documented upregulation of rictor including lung cancer, sarcoma, neuroendocrine prostate, esophagus and stomach cancers, rendering this protein as a potential therapeutic target [25]. Additionally, in glioblastoma multiforme (GBM), epidermal growth factor receptor (EGFR) and rictor-mediated pathways have been shown to play a key role in chemoresistance (increased viability) [26]. The combination of everolimus (mTOR inhibitor) and olaparib (PARPi) has been tested in BRCA2-mutated breast cancer patient-derived xenografts (PDX) with promising results.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status

Saravi

Alizzi

Tosi

et al. 2021

Cells

View full text Add to dashboard Cite

Background: Approximately 50% of ovarian cancer patients harbour homologous recombination repair deficiencies. These deficiencies have been successfully targeted using poly (ADP-ribose) polymerase inhibitors (PARPi) particularly for patients harbouring BRCA1/2 mutations. The aim of this study is to assess the effects of the PARPi rucaparib in vitro using cell lines with BRCA2 mutations in comparison to those with BRCA2 wild type. Methods: Cell proliferation assays, RT-qPCR, immunofluorescence, annexin V/PI assays were used to assess the effects of rucaparib in vitro. Results: The BRCA2 mutant ovarian cancer cell line PEO1 exhibited higher PARP1 activity when treated with H2O2 compared to wild type cell lines. The migratory and proliferative capacity of PEO1 cells was compromised following treatment with rucaparib 10 µM compared to BRCA2 wild-type cell lines via a mechanism involving the mTOR pathway. Rucaparib treatment significantly increased DNA damage primarily in PEO1 cells and SKOV3 cells compared with wild type. Conclusions: Appropriate identification of robust predictive biomarkers for homologous recombination deficiency using ‘liquid’ biopsies would facilitate the identification of patients suitable for PARPi therapy. Preliminary efforts to undertake such testing are described here. This study also demonstrates the mechanisms of action of rucaparib (PARPi) which may involve elements of the mTOR pathway.

show abstract

mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme

Cited by 20 publications

References 206 publications

Vorinostat (SAHA) and Breast Cancer: An Overview

Vorinostat (SAHA) and Breast Cancer: An Overview

Downregulation of NEDD4L by EGFR signaling promotes the development of lung adenocarcinoma

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status

Contact Info

Product

Resources

About